Abercrombie & Fitch lifts fourth-quarter sales target on strong holiday demand
Abercrombie & Fitch on Monday raised its annual net sales growth target for the current quarter helped by strong demand for ...
JD Supra4h
2025 Year in Preview: Antitrust Trends and Key Decisions in Private Litigation
promises a dynamic and challenging year for businesses as key antitrust cases set new precedent, private antitrust litigation will intensify, ...
Buy these 40 smaller stocks with up to 106% upside despite higher interest rates: UBS
Small- and mid-sized companies have consistently trailed large caps, but UBS believes that may change. Here are 40 top ...
GlobalData on MSN2d
Protein pioneers: The countries that have approved cultivated meat
There has been tremendous interest in cell-based meat, not least for its touted long-term potential to aid world food security.
Hosted on MSN6d
[New Insight] iGenics Vision Formula: Expert Analysis and Startling Consumer Complaints
Maintaining good eyesight is more critical than ever in today's fast-paced world. With rising screen time and environmental ...
Ever-Growing USA on MSN2d
I Tried Whispeara for My Hearing Issues—Here’s My Honest Review After 60 Days!
In today's fast-paced world, where noise pollution seems to be an ever-increasing nuisance, the importance of hearing health ...
Energy Matters5d
How Smart Energy Meters Work with Solar Systems
Discover how smart energy meters enhance solar systems, ensuring accurate billing, maximized feed-in tariffs, and optimized ...
Business Insider5d
Intra-Cellular price target raised to $118 from $100 at BofA
BofA raised the firm’s price target on Intra-Cellular (ITCI) to $118 from $100 and keeps a Buy rating on the shares after the company announced a favorable Caplyta patent settlement with Sandoz ...
Investing7d
BofA raises Intra-Cellular stock target to $118 on patent deal
On Friday, BofA Securities analyst Jason Gerberry increased the price target on Intra-Cellular Therapies (NASDAQ:ITCI) to $118 from the previous $110, while maintaining a Buy rating for the ...
Investing4d
Intra-Cellular Therapies stock target raised by Mizuho, Outperform reaffirmed
On Monday, Mizuho (NYSE:MFG) Securities updated its financial outlook for Intra-Cellular Therapies (NASDAQ:ITCI), increasing the stock's price target from $100 to $140 while maintaining an ...
Dow adds more than 350 points, but Nasdaq closes lower as investors rotate out of tech: Live updates
The Dow Jones Industrial Average climbed Monday, outperforming the market, while the Nasdaq Composite slipped as traders ...